Get the Stockscreener App
26.26
3.06%
-0.83
After Hours:
26.26
Pacira Biosciences Inc Stock (PCRX) Latest News
Class Action Filed Against Pacira BioSciences, Inc. (PCRX) Seeking Recovery for Investors – Contact The Gross Law Firm - GlobeNewswire Inc.
PCRXPacira BioSciences, Inc. Latest Stock News & Market Updates - StockTitan
Is Pacira BioSciences Inc (PCRX) a good investment opportunity? - US Post News
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Executive Shakeup at Pacira: New CCO and CBO Join with Multimillion-Dollar Equity Package - StockTitan
Pacira BioSciences, Inc. Stock News: Shareholder Rights Law Firm Robbins LLP Encourages PCRX Stockholders with Large Losses to Contact the Firm to Learn About Their Rights in Connection with the Class Action - PR Newswire
PACIRA BIOSCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF - The Bakersfield Californian
PACIRA BIOSCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS - GlobeNewswire
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Pacira BioSciences, Inc. Investors to - The Bakersfield Californian
Should You Buy Pacira (PCRX) After Golden Cross? - Zacks Investment Research
Pacira BioSciences, Inc. (NASDAQ:PCRX) Holdings Lifted by Gagnon Securities LLC - MarketBeat
The Recovery Playbook: Non-Opioid Pain Management Options After Surgery - NOLA.com
PACIRA BIOSCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA - GlobeNewswire
PACIRA BIOSCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Pacira Biosciences, Inc. of Class Action Lawsuit and Upcoming DeadlinesPCRX - PR Newswire
Lowey Dannenberg Notifies Pacira Biosciences, Inc. - GlobeNewswire
Upward Trajectory: Pacira BioSciences Inc (PCRX) Posts a Slidee, Closing at 25.75 - The Dwinnex
Views of Wall Street’s Leading Experts on Pacira BioSciences Inc - SETE News
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira - GlobeNewswire
IMPORTANT NOTICE: IF YOUR FINANCIAL ADVISOR RECOMMENDED PACIRA BIOSCIENCES INVESTMENTS PLEASE CONTACT KT LAW - EIN News
Pacira BioSciences Inc (PCRX) Becoming More Attractive for Investors - Knox Daily
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 14, 2025 in Pacira LawsuitPCRX - PR Newswire
PCRX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Pacira BioSciences, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Sold by SG Americas Securities LLC - Defense World
Shareholders that lost money on Pacira BioSciences, Inc. - GlobeNewswire
Pacira BioSciences (NASDAQ:PCRX) Stock Rating Upgraded by Truist Financial - MarketBeat
Shareholders that lost money on Pacira BioSciences, Inc. (PCRX) should contact The Gross Law Firm about pending Class ActionPCRX - yourbigsky.com
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Pacira BioSciences, Inc.(PCRX) Shareholders - PR Newswire
ROSEN, A HIGHLY RECOGNIZED FIRM, Encourages Pacira - GlobeNewswire
ROSEN, A HIGHLY RECOGNIZED FIRM, Encourages Pacira BioSciences, Inc. Investors to Secure - The Bakersfield Californian
PCRX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Pacira upgraded at Truist citing end to eVenus patent dispute - MSN
Nisa Investment Advisors LLC Boosts Stock Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Pacer Advisors Inc. Lowers Position in Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat
PACIRA BIOSCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira - Longview News-Journal
Pacira BioSciences soars 62% following InvestingPro's October Fair Value alert - MSN
PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit - PR Newswire
PCRX Stockholders Should Contact Shareholder Rights Firm - GlobeNewswire
Pacira BioSciences soars 62% following InvestingPro's October Fair Value alert By Investing.com - Investing.com Canada
Investors in Pacira BioSciences, Inc. Should Contact Levi & Korsinsky Before March 14, 2025 to Discuss Your RightsPCRX - Victoria Advocate
PCRX Stockholders Have Opportunity to Lead Pacira BioSciences, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - Markets Insider
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira - Marketscreener.com
What 8 Analyst Ratings Have To Say About Pacira BioSciences - Benzinga
Pacira BioSciences stock upgraded at Truist (PCRX:NASDAQ) - Seeking Alpha
PCRX LAWSUIT ALERT: Levi & Korsinsky Notifies Pacira - GlobeNewswire
Pacira Announces Updates to Board of Directors - GlobeNewswire
Pacira Pharmaceuticals Implements New Board Leadership for Growth - TipRanks
Truist Upgrades Pacira Biosciences to Hold From Sell, Boosts Price Target to $25 From $8 - Marketscreener.com
Pacira BioSciences (NASDAQ:PCRX) Has A Rock Solid Balance Sheet - Simply Wall St
The Gross Law Firm Notifies Shareholders of Pacira BioSciences, Inc. (PCRX) of a Class Action Lawsuit and an Upcoming Deadline - PR Newswire
PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
PCRX Shareholders Have Opportunity to Lead Pacira BioSciences, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - Markets Insider
Investors in Pacira BioSciences, Inc. Should Contact The - GlobeNewswire
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira - GlobeNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Pacira Biosciences, Inc. of Class Action Lawsuit and Upcoming DeadlinesPCRX - PR Newswire
0.25%
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):